Working with industry
Positive reasons for bringing commercial research into the UK
The Group unites leading MND researchers across the whole of the UK. Established in 2009, the group is composed of world-class experts in MND, with experienced researchers and patient advocacy groups working together to promote research to develop better treatments and care for people affected by MND.
We work with industry to support early feasibility assessments, and to quickly identify sites that have the capabilities and capacity to deliver their trial. Group membership represents research sites across the whole of the UK. By working directly with investigators, rather than their R&D units, we are able to provide accurate and up-to-date information, and implement strategies to increase capacity or develop capabilities to support MND trials. We encourage commercial sponsors to engage with our group at the earliest stages of development, to ensure we can feed into study designs and ensure they will be deliverable in the UK.
Guidance Tool for costing clinical trials
The group has created a costing guidance tool, aimed at helping industry and trial sites determine fair and uniform costing throughout all clinical trial sites in the UK.
Download the guidance document here: Clinical Trial Costing Guidance for MND
The intention is to encourage sponsors to utilise this guidance when they first generate a study budget in the national costing tool (the NIHR interactive costing tool, or iCT), and then support the lead site when they review the budget during the national contract value review. The goal is to reduce the need for protracted budget negotiations at each site, therefore reducing workload and speeding up set-up; and to have a fairer and more transparent costing process so that there is less budget variability between sites.
For additional information or to discuss how the MND CSG can help industry and sites with trial costings please contact email@example.com
Early feasibility assessment
Identifying participating sites
Group membership represents research sites across the whole of the UK, and members work closely with other investigators within their region, to ensure that the Group is able to reach the whole of the UK. We have intelligence on the facilities and capabilities that each site has, along with their capacity for new trials. This information allows us to work with industry partners to quickly identify potential sites with the capabilities to delivery their trial, facilitate quick communications and support investigators to reduce repetition of information regularly requested in expressions of interest. By working directly with investigators, rather than their R&D units, we are able to provide accurate and up-to-date information, and implement strategies to increase capacity or develop capabilities to support MND trials.
Ways of working
The group works closely with our partners, including: